

SYNLAB Agreements Signed in Poland, Hungary, Romania & Croatia

- Microba and SYNLAB continue to expand distribution of Microba's testing technology across Europe
- Microba has executed four further distribution agreements with SYNLAB affiliate organisations in Poland, Hungary, Romania & Croatia
- This further adds to the new agreements executed with SYNLAB affiliate organisations in March 2023 for Türkiye and Czech Republic

Microba Life Sciences Limited (ASX: MAP) ("Microba") is pleased to announce that agreements have been executed with SYNLAB International GmbH ("SYNLAB") (ETR: SYAB) affiliate organisations SYNLAB Polska Sp, SYNLAB Hungary KFT, LABORATOARELE SYNLAB SRL and SYNLAB HRVATSKA to distribute Microba's testing technology into Poland, Hungary, Romania & Croatia respectively.

Microba's Senior Vice President - Services, Mr Bernie Woodcroft said, *"The addition of these 4 new SYNLAB organisations brings us to 9 SYNLAB countries now distributing our world-leading testing technology. We have been diligently working with SYNLAB executives to sequentially roll out Microba's testing across the SYNLAB affiliate organisation network which is represented throughout Europe and Latin America. We are pleased with our progress as we sign, operationalise, activate sales and marketing, and support growth with these partners. Adding Poland, Hungary, Romania & Croatia delivers further progress in Microba's global distribution strategy, and progresses our major partnership with SYNLAB, Europe's largest medical diagnostics company"*.

In 2020, Microba entered into a master agreement with SYNLAB International GmbH and an agreement with SYNLAB Diagnosticos Globales to deliver Microba's testing technology to Healthcare Providers in Spain, with an option to formalise distribution agreements across their affiliate organisations, which operate in 36 countries. With positive sales and customer feedback in Spain, in October 2022 SYNLAB further activated their rights through an amendment to the master agreement with Microba to pursue formal expansion into additional countries across Europe and Latin America. Aligned to this, in December 2022 a first group of agreements with SYNLAB affiliate organisations for Italy and Portugal were signed, and further in March 2023 a second group signed for Türkiye and Czech Republic.

Entry into Poland, Hungary, Romania & Croatia represents another positive advancement in distribution with Europe's largest medical diagnostics company. Further affiliate country agreements are anticipated to be completed in the near term to continue this expansion activity with SYNLAB.

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

About SYNLAB

SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates. SYNLAB operates in 36 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. Around 30,000 employees, including over 2,000 medical experts, contribute every day to the Group's worldwide success.

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.